Xeris Biopharma Hits Day Low of $5.80 Amid Price Pressure

Xeris Biopharma Holdings, Inc. experienced a significant decline today, with the stock dropping by 9.2% and reaching an intraday low of USD 5.80. This performance stands in contrast to the S&P 500, which saw a modest decrease of 0.43% on the same day. Over the past week, Xeris has faced a 7.41% decline, and its monthly performance reflects an 18.51% drop, indicating a challenging period for the small-cap pharmaceutical and biotechnology company. Despite the recent downturn, Xeris Biopharma has shown resilience over the past year, boasting a remarkable 62.77% increase in stock value compared to the S&P 500's 17.36% gain. The company has reported strong operating cash flow, reaching USD 10.56 million, and net sales of USD 74.38 million, highlighting its operational strengths. However, it also faces challenges, including a negative book value and a high debt-to-EBITDA ratio, which may impact its long-term financial stability. With institutional holdings at 65.61%, Xeris remains a notable player in the pharmaceuticals and biotechnology sector.